Compare EVAX & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | NMTC |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 29.2M |
| IPO Year | 2020 | 2010 |
| Metric | EVAX | NMTC |
|---|---|---|
| Price | $3.13 | $3.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $11.67 | ★ $11.90 |
| AVG Volume (30 Days) | ★ 28.5K | 23.9K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,097,692.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $328.20 | $31.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 163.47 |
| 52 Week Low | $2.28 | $0.55 |
| 52 Week High | $12.15 | $5.40 |
| Indicator | EVAX | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 39.79 |
| Support Level | $2.92 | $0.69 |
| Resistance Level | $3.62 | $4.87 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 21.91 | 27.18 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.